Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Sio Capital Management LLC

Sio Capital Management LLC lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 17.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 127,511 shares of the medical equipment provider's stock after selling 27,793 shares during the quarter. Zimmer Biomet accounts for about 5.5% of Sio Capital Management LLC's investment portfolio, making the stock its 4th largest position. Sio Capital Management LLC owned about 0.06% of Zimmer Biomet worth $13,765,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Ashton Thomas Securities LLC acquired a new position in Zimmer Biomet in the 3rd quarter valued at approximately $28,000. Bangor Savings Bank acquired a new position in shares of Zimmer Biomet in the third quarter valued at $31,000. Family Firm Inc. bought a new position in Zimmer Biomet in the second quarter worth $33,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet during the third quarter worth $35,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Zimmer Biomet in the 2nd quarter valued at $43,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZBH has been the topic of a number of recent research reports. Wolfe Research assumed coverage on Zimmer Biomet in a report on Tuesday, September 10th. They set a "peer perform" rating on the stock. JPMorgan Chase & Co. dropped their price objective on Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating for the company in a research note on Monday, September 16th. Royal Bank of Canada boosted their target price on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an "outperform" rating in a research note on Monday, November 4th. Evercore ISI dropped their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating for the company in a research report on Tuesday, October 1st. Finally, Wells Fargo & Company boosted their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of "Hold" and a consensus target price of $123.22.

Zimmer Biomet Trading Up 0.1 %

Shares of NYSE:ZBH traded up $0.08 during midday trading on Friday, hitting $112.10. The company had a trading volume of 504,048 shares, compared to its average volume of 1,494,978. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90. The firm has a fifty day simple moving average of $107.18 and a 200 day simple moving average of $109.50. The stock has a market cap of $22.32 billion, a price-to-earnings ratio of 21.30, a PEG ratio of 2.06 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter last year, the firm earned $1.65 EPS. Zimmer Biomet's quarterly revenue was up 4.1% compared to the same quarter last year. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.